{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dose+level+2%2FMTD&page=50",
    "query": {
      "intervention": "Dose level 2/MTD",
      "page": 50
    },
    "page_size": 10
  },
  "pagination": {
    "page": 50,
    "page_size": 10,
    "total_count": 1606,
    "total_pages": 161,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dose+level+2%2FMTD&page=51&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dose+level+2%2FMTD&page=49&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-19T07:30:41.632Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04588545",
      "title": "Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "HER2-positive Breast Cancer",
        "Leptomeningeal Metastasis",
        "Leptomeningeal Disease"
      ],
      "interventions": [
        {
          "name": "Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Pertuzumab",
          "type": "DRUG"
        },
        {
          "name": "Trastuzumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "DRUG"
      ],
      "sponsor": "H. Lee Moffitt Cancer Center and Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 33,
      "start_date": "2020-12-10",
      "completion_date": "2027-05",
      "has_results": false,
      "last_update_posted_date": "2026-05-26",
      "last_synced_at": "2026-11-19T07:30:41.632Z",
      "location_count": 2,
      "location_summary": "Tampa, Florida • Evanston, Illinois",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Evanston",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04588545"
    },
    {
      "nct_id": "NCT04017130",
      "title": "A Study of MT-0169 in Participants With Relapsed or Refractory Multiple Myeloma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Relapsed and/or Refractory Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "MT-0169",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Molecular Templates, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 14,
      "start_date": "2020-02-05",
      "completion_date": "2023-12-13",
      "has_results": false,
      "last_update_posted_date": "2024-01-17",
      "last_synced_at": "2026-11-19T07:30:41.632Z",
      "location_count": 7,
      "location_summary": "Los Angeles, California • Jacksonville, Florida • Miami, Florida + 4 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04017130"
    },
    {
      "nct_id": "NCT00733798",
      "title": "A Safety and Efficacy Study of Intravenous 131I-TM601 in Adult Patients With Malignant Melanoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Melanoma",
        "Malignant Melanoma",
        "Metastatic Melanoma"
      ],
      "interventions": [
        {
          "name": "131I-TM601",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "TransMolecular",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 58,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2009-05-11",
      "last_synced_at": "2026-11-19T07:30:41.632Z",
      "location_count": 3,
      "location_summary": "Grand Rapids, Michigan • New York, New York • Dallas, Texas",
      "locations": [
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00733798"
    },
    {
      "nct_id": "NCT00328614",
      "title": "Samarium-153 With Neoadjuvant Hormonal and Radiation Therapy for Locally Advanced Prostate Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Samarium-153",
          "type": "DRUG"
        },
        {
          "name": "Total Androgen Suppression (TAS) with Bicalutamide",
          "type": "DRUG"
        },
        {
          "name": "Total androgen suppression (TAS) with Goserelin Acetate",
          "type": "DRUG"
        },
        {
          "name": "Radiation Therapy",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 32,
      "start_date": "2003-03",
      "completion_date": "2011-06",
      "has_results": true,
      "last_update_posted_date": "2025-05-16",
      "last_synced_at": "2026-11-19T07:30:41.632Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00328614"
    },
    {
      "nct_id": "NCT02779855",
      "title": "Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer",
        "Ductal Carcinoma",
        "Invasive Breast Carcinoma",
        "Invasive Ductal Breast Carcinoma"
      ],
      "interventions": [
        {
          "name": "Talimogene laherparepvec",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "H. Lee Moffitt Cancer Center and Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 50,
      "start_date": "2017-05-02",
      "completion_date": "2025-08-26",
      "has_results": true,
      "last_update_posted_date": "2026-03-10",
      "last_synced_at": "2026-11-19T07:30:41.632Z",
      "location_count": 1,
      "location_summary": "Tampa, Florida",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02779855"
    },
    {
      "nct_id": "NCT01511536",
      "title": "Cabazitaxel and Abiraterone Acetate in Patients With Metastatic Castrate-Resistant Prostate Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Cabazitaxel XRP6258",
          "type": "DRUG"
        },
        {
          "name": "Abiraterone acetate",
          "type": "DRUG"
        },
        {
          "name": "Prednisone 5 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 38,
      "start_date": "2012-03",
      "completion_date": "2014-12",
      "has_results": true,
      "last_update_posted_date": "2016-07-28",
      "last_synced_at": "2026-11-19T07:30:41.632Z",
      "location_count": 2,
      "location_summary": "San Francisco, California • New Haven, Connecticut",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01511536"
    },
    {
      "nct_id": "NCT07463599",
      "title": "Safety and Efficacy of Tegavivint in Patients With Metastatic Colorectal Carcinoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Colorectal Carcinoma (mCRC)",
        "Colorectal Cancer (CRC)",
        "Adenomatous Polyposis Coli (APC) Gene Mutation",
        "Catenin Beta-1 (CTNNB1) Gene Mutation"
      ],
      "interventions": [
        {
          "name": "Tegavivint",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "HonorHealth Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 126,
      "start_date": "2026-02-17",
      "completion_date": "2029-07",
      "has_results": false,
      "last_update_posted_date": "2026-03-11",
      "last_synced_at": "2026-11-19T07:30:41.632Z",
      "location_count": 1,
      "location_summary": "Scottsdale, Arizona",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07463599"
    },
    {
      "nct_id": "NCT03942211",
      "title": "A Study in Participants With Sarcoidosis-associated Pulmonary Hypertension (SAPH) to Assess the Efficacy and Safety of Oral Selexipag",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Sarcoidosis-associated Pulmonary Hypertension"
      ],
      "interventions": [
        {
          "name": "Selexipag",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Actelion",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 10,
      "start_date": "2021-02-26",
      "completion_date": "2023-04-19",
      "has_results": true,
      "last_update_posted_date": "2024-05-08",
      "last_synced_at": "2026-11-19T07:30:41.632Z",
      "location_count": 8,
      "location_summary": "Indianapolis, Indiana • New Orleans, Louisiana • New York, New York + 5 more",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03942211"
    },
    {
      "nct_id": "NCT04330664",
      "title": "Adagrasib in Combination With TNO155 in Patients With Cancer (KRYSTAL 2)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Cancer",
        "Metastatic Cancer",
        "Malignant Neoplastic Disease"
      ],
      "interventions": [
        {
          "name": "MRTX849",
          "type": "DRUG"
        },
        {
          "name": "TNO155",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mirati Therapeutics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 86,
      "start_date": "2020-04-07",
      "completion_date": "2025-02-24",
      "has_results": false,
      "last_update_posted_date": "2025-04-04",
      "last_synced_at": "2026-11-19T07:30:41.632Z",
      "location_count": 17,
      "location_summary": "Los Angeles, California • Orange, California • Chicago, Illinois + 9 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Wichita",
          "state": "Kansas"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04330664"
    },
    {
      "nct_id": "NCT02498912",
      "title": "Cyclophosphamide Followed by Intravenous and Intraperitoneal Infusion of Autologous T Cells Genetically Engineered to Secrete IL-12 and to Target the MUC16ecto Antigen in Patients With Recurrent MUC16ecto+ Solid Tumors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumors"
      ],
      "interventions": [
        {
          "name": "Production of Genetically-modified T cells",
          "type": "PROCEDURE"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "IP Catheter Insertion",
          "type": "DEVICE"
        },
        {
          "name": "Infusion of 4H11-28z/fIL-12/EGFRt+ Genetically-modified T cells",
          "type": "GENETIC"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "DEVICE",
        "GENETIC"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 18,
      "start_date": "2015-08",
      "completion_date": "2027-08",
      "has_results": false,
      "last_update_posted_date": "2026-09-29",
      "last_synced_at": "2026-11-19T07:30:41.632Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02498912"
    }
  ]
}